Navigation Links
Vermillion Retains ThinkPanmure to Assist in the Evaluation of Potential Strategic Alternatives
Date:7/14/2008

FREMONT, Calif., July 14 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Nasdaq: VRML), a molecular diagnostics company, today announced that it has engaged ThinkPanmure LLC., a global, growth-company investment bank, to assist the Company in identifying and evaluating strategic alternatives intended to enhance the potential of the Company's proteomic tests (OVA1(TM) and VASCLIR(TM)) and pipeline of proprietary biomarkers to maximize stockholder value. No assurances can be given that this evaluation will lead to any specific action or transaction.

"We continuously evaluate our strategic options to identify and develop prospects for maximizing value for all stockholders and look forward to working with ThinkPanmure in this regard," said Gail Page, President and Chief Executive Officer of Vermillion. "While reviewing the various alternatives, we will continue to advance our commercialization strategies, namely building marketplace awareness for our women's health, oncology, and cardiac programs which include the OVA1(TM) and VASCLIR(TM) tests."

About ThinkPanmure LLC

ThinkPanmure LLC is a research-centric institutional investment bank focused on the growth economy. ThinkPanmure LLC is dedicated to providing strategic advice, in-depth research coverage and capital to corporate clients and institutional investors interested in the knowledge economy's key growth verticals: consumer business services, healthcare, media, and technology. For more information about ThinkPanmure LLC, please visit http://www.thinkpanmure.com. Member NASD and SIPC.

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Vermillion is based in Fremont, California. Additional information about Vermillion can be found on the Web at http://www.vermillion.com.

Forward Looking Statements

This news release contains forward-looking statements that involve significant risks and uncertainties, including the risks and uncertainties discussed in Vermillion's Form 10-K for the year ended December 31, 2007, and Vermillion's periodic reports on Form 10-Q and Form 8-K. Vermillion is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise. In particular, there can be no assurance that Vermillion will enter into a strategic transaction, that, if any transaction is commenced, it will be completed or as to the value that any such transaction might have for Vermillion's stockholders. Forward-looking statements cannot be guaranteed and actual results may differ materially from Vermillion's current expectations. You are encouraged to read Vermillion's reports filed with the U.S. Securities and Exchange Commission, available at http://www.sec.gov.


'/>"/>
SOURCE Vermillion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vermillion to Host Live Roundtable Discussion With Principal Investigator of OVA1(TM) Submission
2. Vermillion Announces First Quarter 2008 Financial Results and Business Progress
3. Vermillions Roundtable Teleconference Highlights Peripheral Artery Disease Diagnostic Program; Features Commentary from Vascular Medicine Expert
4. Vermillion Announces Appointment of John Hamilton to Board of Directors
5. Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease
6. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
7. Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones
8. Vermillion Announces Effectiveness of Reverse Stock Split
9. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
10. Vermillion Receives NASDAQ Notice of Non-Compliance
11. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2017)... ... July 17, 2017 , ... Neurodevelopmental disorders ... range of overlapping clinical features. The advancement of targeted next-generation sequencing (NGS) has ... research and testing. , However, designing a custom panel for disease research ...
(Date:7/17/2017)... , ... July 17, 2017 , ... ... company that has developed and intends both to manufacture and sell reagents used ... the NASDAQ Capital Market. , Headquartered in Sandy, Utah, Co-Diagnostics’ intellectual property and ...
(Date:7/16/2017)... ... July 16, 2017 , ... OHAUS Corporation, a leading worldwide ... its new line of Rocking and Waving Shakers today. , Five New Models ... and digital) for laboratory applications in a variety of environmental conditions. Rocking shakers ...
(Date:7/15/2017)... ... July 15, 2017 , ... Cuvette manufacturer FireflySci has ... this time, the people at FFS have learned that their biggest asset was their ... are able to launch new products to meet the changing needs of scientists at ...
Breaking Biology Technology:
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... grow at a CAGR of 30.37% during the period 2017-2021. ... prepared based on an in-depth market analysis with inputs from industry ... over the coming years. The report also includes a discussion of ...
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
Breaking Biology News(10 mins):